[
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know",
    "summary": "Eli Lilly (LLY) closed at $1 in the latest trading session, marking a -2.12% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=92d5c0cb66e70aa0422bcf8374d34aaabfde0c7e0089b41f509d2db853dadf54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769208303,
      "headline": "Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know",
      "id": 138229907,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) closed at $1 in the latest trading session, marking a -2.12% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=92d5c0cb66e70aa0422bcf8374d34aaabfde0c7e0089b41f509d2db853dadf54"
    }
  },
  {
    "ts": null,
    "headline": "Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly",
    "summary": "Shares of Altimmune (NASDAQ:ALT) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit. The clinical-stage biotech develops treatments for metabolic diseases and became one of the highest-rated stocks in social sentiment tracking after the FDA granted Breakthrough Therapy Designation for its lead drug pemvidutide on January 16. ... Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly",
    "url": "https://finnhub.io/api/news?id=1daf049c39fbca9e13fe510e58893d7091cd7bf100ab398e1397b132a9c7fddd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769195194,
      "headline": "Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly",
      "id": 138229280,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of Altimmune (NASDAQ:ALT) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit. The clinical-stage biotech develops treatments for metabolic diseases and became one of the highest-rated stocks in social sentiment tracking after the FDA granted Breakthrough Therapy Designation for its lead drug pemvidutide on January 16. ... Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly",
      "url": "https://finnhub.io/api/news?id=1daf049c39fbca9e13fe510e58893d7091cd7bf100ab398e1397b132a9c7fddd"
    }
  },
  {
    "ts": null,
    "headline": "Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?",
    "summary": "Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.",
    "url": "https://finnhub.io/api/news?id=921ed78dba5a3de16564bf3d9a0f6185fc07cb3cdabc7269749e54bbca782115",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769191500,
      "headline": "Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?",
      "id": 138228445,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.",
      "url": "https://finnhub.io/api/news?id=921ed78dba5a3de16564bf3d9a0f6185fc07cb3cdabc7269749e54bbca782115"
    }
  },
  {
    "ts": null,
    "headline": "NVIDIA (NVDA) Invests $150 million in Baseten",
    "summary": "NVIDIA Corporation (NASDAQ:NVDA) is one of the Best Quantum Computing Stocks to Buy for 2026. On January 20, WSJ reported that the company is investing $150 million in Baseten, a startup that specializes in AI inference. Baseten has raised $300 million at a $5 billion valuation. This deal demonstrates NVIDIA Corporation (NASDAQ:NVDA)’s aggressive push into […]",
    "url": "https://finnhub.io/api/news?id=20a6c90e91eec1d7a8f44f607439ef250d224eff418ac93a76db9fd229908176",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769189603,
      "headline": "NVIDIA (NVDA) Invests $150 million in Baseten",
      "id": 138226851,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVIDIA Corporation (NASDAQ:NVDA) is one of the Best Quantum Computing Stocks to Buy for 2026. On January 20, WSJ reported that the company is investing $150 million in Baseten, a startup that specializes in AI inference. Baseten has raised $300 million at a $5 billion valuation. This deal demonstrates NVIDIA Corporation (NASDAQ:NVDA)’s aggressive push into […]",
      "url": "https://finnhub.io/api/news?id=20a6c90e91eec1d7a8f44f607439ef250d224eff418ac93a76db9fd229908176"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rebounds As Weight-Loss Drug Battle Continues",
    "summary": "Eli Lilly stock has been climbing back from a recent pullback and nearing a buy point. The drugmaker teamed up with Nvidia on a new project.",
    "url": "https://finnhub.io/api/news?id=97e0bf4727146630488a61fbc2a12c1107643a4a665d0b5b152bcdb3a106d6a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769187970,
      "headline": "Eli Lilly Stock Rebounds As Weight-Loss Drug Battle Continues",
      "id": 138226854,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock has been climbing back from a recent pullback and nearing a buy point. The drugmaker teamed up with Nvidia on a new project.",
      "url": "https://finnhub.io/api/news?id=97e0bf4727146630488a61fbc2a12c1107643a4a665d0b5b152bcdb3a106d6a3"
    }
  },
  {
    "ts": null,
    "headline": "Why a 15% Dividend Wasn’t Enough to Keep This $3.3 Million Position",
    "summary": "Trinity Capital provides venture debt and equipment financing to growth-stage tech companies seeking non-dilutive capital solutions.",
    "url": "https://finnhub.io/api/news?id=0500deeddc3b02f7dc6c01d8256686e1c90592c248a6f948fe626bc0776e4f31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769183447,
      "headline": "Why a 15% Dividend Wasn’t Enough to Keep This $3.3 Million Position",
      "id": 138225571,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Trinity Capital provides venture debt and equipment financing to growth-stage tech companies seeking non-dilutive capital solutions.",
      "url": "https://finnhub.io/api/news?id=0500deeddc3b02f7dc6c01d8256686e1c90592c248a6f948fe626bc0776e4f31"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: This Run Is Just Getting Started",
    "summary": "Novo Nordisk A/S is rated a Buy with solid long-term prospects, and the stock appears undervalued. Learn more about NVO stock here.",
    "url": "https://finnhub.io/api/news?id=699e0e89bd929ba43ec087a27b212bfea84c4fdd3517b973abdb13f10c31709c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769182904,
      "headline": "Novo Nordisk: This Run Is Just Getting Started",
      "id": 138229027,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305433/image_2158305433.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S is rated a Buy with solid long-term prospects, and the stock appears undervalued. Learn more about NVO stock here.",
      "url": "https://finnhub.io/api/news?id=699e0e89bd929ba43ec087a27b212bfea84c4fdd3517b973abdb13f10c31709c"
    }
  },
  {
    "ts": null,
    "headline": "VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion",
    "summary": "The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution. The fund’s concentrated bet on GLP-1 manufacturers makes this a call option on the market’s continued growth. Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) combined represented nearly one-third of the ETF. If you believe the ... VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion",
    "url": "https://finnhub.io/api/news?id=f09384037823b06108c46f090642fce1be1e770587275b0673a3629195b85fd8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769182600,
      "headline": "VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion",
      "id": 138226911,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution. The fund’s concentrated bet on GLP-1 manufacturers makes this a call option on the market’s continued growth. Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) combined represented nearly one-third of the ETF. If you believe the ... VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion",
      "url": "https://finnhub.io/api/news?id=f09384037823b06108c46f090642fce1be1e770587275b0673a3629195b85fd8"
    }
  },
  {
    "ts": null,
    "headline": "Outfront Media Surges 40% in One Year, Then Gets Cut Loose Despite 'Exceptional Performance'",
    "summary": "This out-of-home advertising REIT connects brands with urban audiences through a broad network of billboard and transit assets.",
    "url": "https://finnhub.io/api/news?id=5e5e9f46e903ac4621eb5c757a13a2b5d321d541bf765f86717e45a3dff8394e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769181634,
      "headline": "Outfront Media Surges 40% in One Year, Then Gets Cut Loose Despite 'Exceptional Performance'",
      "id": 138225574,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "This out-of-home advertising REIT connects brands with urban audiences through a broad network of billboard and transit assets.",
      "url": "https://finnhub.io/api/news?id=5e5e9f46e903ac4621eb5c757a13a2b5d321d541bf765f86717e45a3dff8394e"
    }
  },
  {
    "ts": null,
    "headline": "Novo's Wegovy pill hits 18,410 US prescriptions in encouraging debut week",
    "summary": "By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed 18,410 times in the U.S. in the first full week after its launch in an encouraging start to the oral weight-loss drug race,",
    "url": "https://finnhub.io/api/news?id=2943bd566d2221e385656b80777f10322bb6bf0107b1bac9a18b61ae608a5743",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769177126,
      "headline": "Novo's Wegovy pill hits 18,410 US prescriptions in encouraging debut week",
      "id": 138225630,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed 18,410 times in the U.S. in the first full week after its launch in an encouraging start to the oral weight-loss drug race,",
      "url": "https://finnhub.io/api/news?id=2943bd566d2221e385656b80777f10322bb6bf0107b1bac9a18b61ae608a5743"
    }
  },
  {
    "ts": null,
    "headline": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings",
    "summary": "LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens beyond GLP-1s.",
    "url": "https://finnhub.io/api/news?id=9b077c59e797e4ea01bcd54334d200de183be16426ec55c70fc8dec1828a99b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769175360,
      "headline": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings",
      "id": 138225631,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens beyond GLP-1s.",
      "url": "https://finnhub.io/api/news?id=9b077c59e797e4ea01bcd54334d200de183be16426ec55c70fc8dec1828a99b0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026",
    "summary": "This biotech has candidates in late-stage clinical development.",
    "url": "https://finnhub.io/api/news?id=8c3bf3e2acb462c864ef416e1d3ed64c88e4eae0fb8448aa245f51e36eb85359",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769164200,
      "headline": "Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026",
      "id": 138223428,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "This biotech has candidates in late-stage clinical development.",
      "url": "https://finnhub.io/api/news?id=8c3bf3e2acb462c864ef416e1d3ed64c88e4eae0fb8448aa245f51e36eb85359"
    }
  },
  {
    "ts": null,
    "headline": "What obesity drugmakers see next in the market: More pills, easier access and drug combinations",
    "summary": "CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.",
    "url": "https://finnhub.io/api/news?id=e69a89e18c4ccf186242eb8613a7743e95e35683e2a2e2fc6f3f0e07e1f5616c",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769151601,
      "headline": "What obesity drugmakers see next in the market: More pills, easier access and drug combinations",
      "id": 138226467,
      "image": "https://image.cnbcfm.com/api/v1/image/108253253-1768511651216-gettyimages-2255813292-WEGOVY_PILLS.jpeg?v=1769106872&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco. ",
      "url": "https://finnhub.io/api/news?id=e69a89e18c4ccf186242eb8613a7743e95e35683e2a2e2fc6f3f0e07e1f5616c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",
    "summary": "AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",
    "url": "https://finnhub.io/api/news?id=7f99158813c633d0e2153683ce19bb53378d72df1f24fbd52fc9338223c80772",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769149800,
      "headline": "AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",
      "id": 138222072,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",
      "url": "https://finnhub.io/api/news?id=7f99158813c633d0e2153683ce19bb53378d72df1f24fbd52fc9338223c80772"
    }
  },
  {
    "ts": null,
    "headline": "2 Mega-Cap Stocks to Target This Week and 1 We Find Risky",
    "summary": "Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.",
    "url": "https://finnhub.io/api/news?id=32293175dda2b41fc17783b5022d0171c335141121c063c8b6c2051457538805",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769142777,
      "headline": "2 Mega-Cap Stocks to Target This Week and 1 We Find Risky",
      "id": 138229281,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.",
      "url": "https://finnhub.io/api/news?id=32293175dda2b41fc17783b5022d0171c335141121c063c8b6c2051457538805"
    }
  }
]